About this trial
Recently a new clinical dementia subgroup based on brain imaging, called "diabetes related dementia (DrD)". DrD, unlike Alzheimer's disease and vascular dementia, is considered a "controllable" or "modifiable" form of dementia. However, there is currently a lack of corresponding treatment measures. Ginkgo biloba ketone ester tablets are extracts of Ginkgo biloba leaves. Previous studies have shown that they can increase cerebral blood flow, reduce cerebrovascular resistance, improve cerebral circulation, and are beneficial for the treatment of cognitive impairment. This project intends to explore the role of ginkgo ketoester tablets in diabetes related dementia through a multicenter randomized double-blind controlled clinical study.
Eligibility criteria
Qualifiers
Type 2 diabetes with mild cognitive impairment patients aged 65 years or above;
Able to cooperate in completing cognitive function testing;
Patients who can swallow pills
No previous history of stroke,cerebral thrombosis, etc
Disqualifiers
Type 1 diabetes;
Acute cerebral infarction and myocardial infarction within 3 months;
Severe liver and kidney dysfunction;
Late stage malignant tumors;
Trial design
Treatments tested in this trial
- Ginkgo Ketone Ester Tablets
- placebo